Merck (MRK) Other financing activities (2009 - 2026)

Merck has disclosed Other financing activities across 18 years of filings, most recently posting -$80.0 million for Q1 2026.

• In Q1 2026, Other financing activities fell 33.33% year-over-year to -$80.0 million; the TTM figure through Mar 2026 stood at -$151.0 million (up 57.34% YoY), while the FY2025 annual figure was -$131.0 million, up 64.78% from the prior year.
• Other financing activities retreated to -$80.0 million in Q1 2026, from $121.0 million in the prior quarter.
• Over the last five years, Other financing activities for MRK reached as high as $121.0 million in Q4 2025 and fell as low as -$234.0 million in Q2 2023.
• The 5-year median for Other financing activities is -$68.0 million (2022), against an average of -$67.7 million.
• Annual changes were most pronounced in 2024 — Other financing activities tumbled 1300.0% — and 2025, when it soared 388.1%.
• A 5-year view of Other financing activities shows it stood at -$68.0 million in 2022, then surged by 95.59% to -$3.0 million in 2023, then plunged by 1300.0% to -$42.0 million in 2024, then jumped by 388.1% to $121.0 million in 2025, then slumped by 166.12% to -$80.0 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered -$80.0 million, $121.0 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.